NCT01774721 - ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | Biotech Hunter

Enrollment

452

Participants

Timeline

Start Date

May 9, 2013

Primary Completion Date

July 29, 2016

Study Completion Date

January 27, 2022

Conditions

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Interventions

DRUG

Dacomitinib (PF-00299804)

Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.

DRUG

Gefitinib

Gefitinib 250 mg tablets, continuous oral daily dosing.

Trial Locations (52)

Unknown

Beijing

Changchun

Changsha

Chengdu

Chongqing

Fuzhou

Guangzhou

Hangzhou

Hefei

Nanning

Shanghai

Shenyang

Tianjin

Wuhan

Wuxi

Hong Kong

Shatin

Catania

Lecco

Livorno

Meldola

Milan

Napoli

Perugia

Ravenna

Roma

Trento

Viterbo

Hokkaido

Kashiwa

Matsuyama

Yokohama

Tokyo

Sakai

Sayama

Sunto-gun

Chuo-Ku

Gdansk

Olsztyn

Poznan

Warsaw

Seoul

Ávila

Barcelona

Bilbao

Cáceres

Córdoba

Donostia / San Sebastian

Las Palmas

Madrid

Málaga

Seville